Metastatic Ability
Metastatic Ability - Related Videos
03:52
Experimental Metastatic Melanoma Mouse Model: A Platform to Study the Metastatic Potential of Melanoma Cells in the Lungs
0 Views •
2023
In this video, melanoma cells are intravenously injected through the tail vein in the mouse model. The melanoma cells further travel through the circulatory system, adapting to the distant microenvironment and causing metastasis in organs like lungs.
11:27
Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
0 Views •
Cited by 23 •
2014
Models of spontaneous metastatic renal cell carcinoma (RCC) disease progression can be used for evaluating treatments in a clinically relevant setting. This protocol demonstrates different procedures for orthotopic kidney tumor cell implantation, proper nephrectomy, and finally outlines a necropsy guide for visual and bioluminescent scoring of metastatic burden and localization.
03:06
The Effect of Aspirin and Ibuprofen on the Phagocytic Ability of Macrophages
0 Views •
2025
Source:Adepemi O. Ogundeji1, Nozethu Mjokane1, Maphori Maliehe1, Olihile M. Sebolai11Department of Microbiology and Biochemistry, University of the Free State.This video showcases a method to assess the impact of aspirin and ibuprofen, at their minimum inhibitory concentrations, on macrophage phagocytosis using pH-sensitive fluorescent dye-stained fungal cells. The drugs inhibit cyclooxygenase-2, decreasing prostaglandin formation and boosting macrophage phagocytosis, as observed through...
09:14
An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth
0 Views •
Cited by 39 •
2011
A modified 3-D in vitro system is presented in which growth characteristics of several tumor cell lines in reconstituted basement membrane correlate with the dormant or proliferative behavior of the tumor cells at a metastatic secondary site in vivo.
07:31
Testing the Vascular Invasive Ability of Cancer Cells in Zebrafish (Danio Rerio)
0 Views •
Cited by 19 •
2016
This method utilizes zebrafish embryos to efficiently test the vascular invasive ability of cancer cells. Fluorescent cancer cells are injected into the precardiac sinus or yolk sac of developing embryos. Cancer cell vascular invasion and extravasation is assessed via fluorescence microscopy of the tail region 24 to 96 hr later.
FAQs
Successful dissemination requires more than movement away from a primary tumor. Cancer cells must invade surrounding tissue, enter blood or lymphatic vessels, remain viable during circulation, leave vessels at a distant site, and adapt to the new tissue microenvironment. Failure at any stage can limit progression, so metastatic ability reflects a coordinated sequence rather than a single cellular behavior.
Blood and lymphatic vessels provide routes through which cancer cells can leave the primary tumor and travel to other parts of the body. Entry into these vessels is followed by survival during circulation and exit at a distant site. Because dissemination can use either route, evaluating metastatic progression requires attention to both vascular pathways rather than local tissue invasion alone.
Reaching a distant site does not by itself ensure formation of a secondary tumor. Cancer cells must adapt to the new tissue microenvironment after exiting the circulation. This requirement helps explain why dissemination and colonization are separate challenges, and why cells capable of traveling may still differ in their ability to establish persistent growth elsewhere.
Local treatment may control or remove the primary tumor without eliminating cancer cells that have already disseminated. Cells that survive elsewhere can later adapt to a distant tissue microenvironment and establish secondary disease. Metastatic ability therefore provides a framework for understanding recurrence after apparently successful local treatment and for considering risks beyond the original tumor site.
Assessment of metastatic ability helps clinicians determine how far cancer has progressed beyond its primary site. This information contributes to prognosis and staging by distinguishing disease that remains local from disease involving distant dissemination. The resulting assessment can also support treatment selection, since the likelihood and extent of spread affect how clinicians interpret the cancer’s clinical significance.
Metastatic ability is relevant to treatment selection because it indicates whether cancer behavior may extend beyond the location of the primary tumor. Information about dissemination can help place local disease findings in a broader clinical context and support decisions aimed at managing progression. It also identifies a rationale for therapies designed to block dissemination or later colonization.
Studies can examine how cancer cells invade tissue, enter and survive within circulation, exit at distant sites, and adapt to new microenvironments. They can also investigate why some tumors disseminate or recur after local treatment. These questions support research into therapies that interrupt particular stages of progression rather than focusing only on the primary tumor.